EGFR and cancer: Certain semaphorins are also promising predictors of the response to anti-cancer therapies, including standard chemo/radiotherapy (e.g. Sema3C, Sema4C), anti-angiogenic drugs (e.g. Sema4D), anti-hormonal treatments (e.g. Sema4C, Sema7A), and other targeted molecular therapies, such as with anti-EGFR inhibitors (Sema7A).